Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Protein and Peptide Letters
  4. Volume 31, Issue 11
  5. Article
Volume 31, Issue 11
  • ISSN: 0929-8665
  • E-ISSN: 1875-5305

Abstract

Background

The abnormal expression of small G protein signaling modulator 2 (SGSM2) is related to the occurrence of thyroid cancer and breast cancer. However, the role of SGSM2 in uveal melanoma (UVM) is unclear.

Objects

To elucidate this ambiguity, our study utilized bioinformatics analysis and experimental validation.

Methods

The expression of SGSM2 was detected in UVM cell lines through quantitative real-time PCR (qRT-PCR). We utilized the Cancer Genome Atlas (TCGA) database to assess the relationship between SGSM2 expression and clinical characteristics, as well as its prognostic significance in UVM. Furthermore, the study examined potential regulatory networks involving SGSM2 in relation to immune infiltration, immune checkpoint genes, microsatellite instability (MSI), and drug sensitivity in UVM. The study also examined SGSM2 expression in UVM single-cell sequencing data.

Results

SGSM2 was highly expressed in UVM cell lines. Moreover, elevated levels of SGSM2 in UVM patients were significantly linked to poorer overall survival (OS) ( 0.001), progress-free survival (PFS) ( 0.001), and disease-specific survival (DSS) ( 0.001). Additionally, SGSM2 expression was identified as an independent prognostic factor in UVM patients ( 0.001). SGSM2 was associated with several pathways, including the calcium signaling pathway, natural killer cell-mediated cytotoxicity, cell adhesion molecules (CAMs), and others. The study revealed that SGSM2 expression in UVM is linked to immune infiltration, immune checkpoint genes, and MSI. Additionally, a significant inverse correlation was observed between SGSM2 expression and the compounds GSK690693, TL-2-105, PHA-793887, Tubastatin A, and SB52334 in UVM patients.

Conclusion

SGSM2 may not only serve as an important indicator for prognostic assessment. Still, it may also be a key target for the development of new therapeutic approaches, providing new perspectives on the treatment of UVM patients.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ppl/10.2174/0109298665341953240926041613
2024-11-04
2025-01-31

  • From This Site

    /content/journals/ppl/10.2174/0109298665341953240926041613
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AronowM.E. TophamA.K. SinghA.D. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013).Ocul. Oncol. Pathol.20184314515110.1159/00048064029765944
     [Google Scholar]
  2. FotiP.V. TravaliM. FarinaR. PalmucciS. SpatolaC. LiardoR.L.E. MilazzottoR. RaffaeleL. SalamoneV. CaltabianoR. BroggiG. PuzzoL. RussoA. ReibaldiM. LongoA. VigneriP. AvitabileT. EttorreG.C. BasileA. Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: Treatment indications and complications.Insights Imaging20211216710.1186/s13244‑021‑01001‑w34085131
     [Google Scholar]
  3. BroggiG. MusumeciG. PuzzoL. RussoA. ReibaldiM. RagusaM. LongoA. CaltabianoR. Immunohistochemical expression of ABCB5 as a potential prognostic factor in uveal melanoma.Appl. Sci. (Basel)201997131610.3390/app9071316
     [Google Scholar]
  4. JagerM.J. ShieldsC.L. CebullaC.M. Abdel-RahmanM.H. GrossniklausH.E. SternM.H. CarvajalR.D. BelfortR.N. JiaR. ShieldsJ.A. DamatoB.E. Uveal melanoma.Nat. Rev. Dis. Primers2020612410.1038/s41572‑020‑0158‑032273508
     [Google Scholar]
  5. GallengaC.E. FrancoE. AdamoG.G. ViolantiS.S. TassinariP. TognonM. PerriP. Genetic basis and molecular mechanisms of uveal melanoma metastasis: A focus on prognosis.Front. Oncol.20221282811210.3389/fonc.2022.82811235480119
     [Google Scholar]
  6. LaneA.M. KimI.K. GragoudasE.S. Survival rates in patients after treatment for metastasis from uveal melanoma.JAMA Ophthalmol.2018136998198610.1001/jamaophthalmol.2018.246629955797
     [Google Scholar]
  7. MarubashiS. ShimadaH. FukudaM. OhbayashiN. RUTBC1 functions as a GTPase-activating protein for Rab32/38 and regulates melanogenic enzyme trafficking in melanocytes.J. Biol. Chem.201629131427144010.1074/jbc.M115.68404326620560
     [Google Scholar]
  8. JiangP. PanY. LiuZ. LiuX. SGSM2, A putative Rab2a GAP, regulates lysozyme sorting in Paneth cells.Sci. China Life Sci.201861786086310.1007/s11427‑017‑9267‑929527623
     [Google Scholar]
  9. NottinghamR.M. GanleyI.G. BarrF.A. LambrightD.G. PfefferS.R. RUTBC1 protein, A Rab9A effector that activates GTP hydrolysis by Rab32 and Rab33B proteins.J. Biol. Chem.201128638332133322210.1074/jbc.M111.26111521808068
     [Google Scholar]
  10. YangH. SasakiT. MinoshimaS. ShimizuN. Identification of three novel proteins (SGSM1, 2, 3) which modulate small G protein (RAP and RAB)-mediated signaling pathway.Genomics200790224926010.1016/j.ygeno.2007.03.01317509819
     [Google Scholar]
  11. SuX. ChenD. ZhuL. JiaH. CaiJ. LiP. HanB. WangD. LiH. FanJ. GuM. ZhouY. GuanH. WeiW. SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibition.Cell Death Dis.202213321810.1038/s41419‑022‑04598‑y35264562
     [Google Scholar]
  12. LinJ.H. LeeW.J. WuH.C. WuC.H. ChenL.C. HuangC.C. ChangH.L. ChengT.C. ChangH.W. HoC.T. TuS.H. HoY.S. Small G protein signalling modulator 2 (SGSM2) is involved in oestrogen receptor-positive breast cancer metastasis through enhancement of migratory cell adhesion via interaction with E-cadherin.Cell Adhes. Migr.201913112113810.1080/19336918.2019.156813930744493
     [Google Scholar]
  13. LinP.C. ChenH.O. LeeC.J. YehY.M. ShenM.R. ChiangJ.H. Comprehensive assessments of germline deletion structural variants reveal the association between prognostic MUC4 and CEP72 deletions and immune response gene expression in colorectal cancer patients.Hum. Genomics2021151310.1186/s40246‑020‑00302‑333431054
     [Google Scholar]
  14. ZhuangA. GuX. GeT. WangS. GeS. ChaiP. JiaR. FanX. Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m6A RNA methylation in ocular melanoma.Cancer Commun. (Lond.)202343111185120610.1002/cac2.1247137466203
     [Google Scholar]
  15. DingX. WanA. QiX. JiangK. LiuZ. ChenB. ZNF695, A potential prognostic biomarker, correlates with immune infiltrates in cervical squamous cell carcinoma and endoce rvical adenocarcinoma: Bioinformatic analysis and experimental verification.Curr. Gene Ther.202424544145210.2174/011566523228521624022807124438441026
     [Google Scholar]
  16. HeH. YuanF. LiY. PiG. ShiH. LiY. HanG. Comprehensive analysis and experimental validation of FOXD2 as a novel potential prognostic biomarker associated with immune infiltration in head and neck squamous cell carcinoma.Curr. Computeraided Drug Des.20242010.2174/011573409930249224040506550538629358
     [Google Scholar]
  17. RenL. PanX. NingL. GongD. HuangJ. DengK. XieL. ZhangY. Construction of a combined hypoxia-related genes model for hepatocellular carcinoma prognosis.Curr. Computeraided Drug Des.202319215016110.2174/157340991966622122312361036567292
     [Google Scholar]
  18. YangD. LiuM. JiangJ. LuoY. WangY. ChenH. LiD. WangD. YangZ. ChenH. Comprehensive analysis of DMRT3 as a potential biomarker associated with the immune infiltration in a pan-cancer analysis and validation in lung adenocarcinoma.Cancers (Basel)20221424622010.3390/cancers1424622036551704
     [Google Scholar]
  19. YiW. ShenH. SunD. XuY. FengY. LiD. WangC. Low expression of long noncoding RNA SLC26A4 antisense RNA 1 is an independent prognostic biomarker and correlate of immune infiltrates in breast cancer.Med. Sci. Monit.202127e93452234880202
     [Google Scholar]
  20. HuaH. PanS. DiaoH. CaoY. QianX. ZhangJ. Increased ACSL6 expression predicts a favorable prognosis in triple-negative breast cancer.Curr. Med. Chem.20243110.2174/010929867327884623122210342038310395
     [Google Scholar]
  21. ChenL. GeM. MoS. ShiM. ZhangJ. LiuJ. Construction of a New Ferroptosis-related Prognosis Model for Survival Prediction in Colorectal Cancer.Curr. Med. Chem.202438362684
     [Google Scholar]
  22. XuY. ShenY. BhandariA. HirachanS. WangO. XiaE. Serine Protease 27, A prognostic biomarker in pan-cancer and associated with the aggressive progression of breast cancer.Curr. Med. Chem.202431152073208910.2174/092986733066623032416132937282654
     [Google Scholar]
  23. ChenY. XuH. TangH. LiH. ZhangC. JinS. BaiD. miR-9-5p expression is associated with vascular invasion and prognosis in hepatocellular carcinoma, and in vitro verification.J. Cancer Res. Clin. Oncol.202314916146571467110.1007/s00432‑023‑05257‑137584711
     [Google Scholar]
  24. RenZ. ZhangX. HanJ. Expression and prognostic significance of ferroptosis-related proteins SLC7A11 and GPX4 in renal cell carcinoma.Protein Pept. Lett.2023301086887610.2174/010929866525570423092006325437807410
     [Google Scholar]
  25. YangE. HongY. XuanC. XuJ. DingQ. ZhaoS. YeH. FanX. JiangZ. ZhangS. DingX. Biomarker of pulmonary inflammatory response in LUAD: miR-584-5p targets RAB23 to suppress inflammation induced by LPS in A549 cells.Protein Pept. Lett.2023301087789010.2174/010929866524892823101807082538093594
     [Google Scholar]
  26. LiangW. LuY. PanX. ZengY. ZhengW. LiY. NieY. LiD. WangD. Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma.Pharm. Genomics Pers. Med.20221598599810.2147/PGPM.S38490136482943
     [Google Scholar]
  27. LiangL. XuH. DongQ. QiuL. LuL. YangQ. ZhaoW. LiY. WTAP is correlated with unfavorable prognosis, tumor cell proliferation, and immune infiltration in hepatocellular carcinoma.Front. Oncol.20221285200010.3389/fonc.2022.85200035480109
     [Google Scholar]
  28. LinZ. HuangW. YiY. LiD. XieZ. LiZ. YeM. LncRNA ADAMTS9-AS2 is a prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma.Int. J. Gen. Med.2021148541855510.2147/IJGM.S34068334849000
     [Google Scholar]
  29. LuX. JingL. LiuS. WangH. ChenB. miR-149-3p is a potential prognosis biomarker and correlated with immune infiltrates in uterine corpus endometrial carcinoma.Int. J. Endocrinol.2022202211510.1155/2022/500612335719192
     [Google Scholar]
  30. BindeaG. MlecnikB. TosoliniM. KirilovskyA. WaldnerM. ObenaufA.C. AngellH. FredriksenT. LafontaineL. BergerA. BrunevalP. FridmanW.H. BeckerC. PagèsF. SpeicherM.R. TrajanoskiZ. GalonJ. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.Immunity201339478279510.1016/j.immuni.2013.10.00324138885
     [Google Scholar]
  31. ChenB. LuX. ZhouQ. ChenQ. ZhuS. LiG. LiuH. PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.PLoS One2023188e029003110.1371/journal.pone.029003137582104
     [Google Scholar]
  32. DuQ. XingN. GuoS. MengX. ZhangY. WangS. Cycas revoluta leaves: As a potential flavonoids source for targeted regulation of immune-related markers in lung adenocarcinoma.Ind. Crops Prod.202320211696710.1016/j.indcrop.2023.116967
     [Google Scholar]
  33. LuZ.M. PanS.L. YuanW.L. FengJ.L. TianD. ShangX.Q. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.Medicine (Baltimore)202310250e3648010.1097/MD.000000000003648038115316
     [Google Scholar]
  34. YoshiharaK. ShahmoradgoliM. MartínezE. VegesnaR. KimH. Torres-GarciaW. TreviñoV. ShenH. LairdP.W. LevineD.A. CarterS.L. GetzG. Stemke-HaleK. MillsG.B. VerhaakR.G.W. Inferring tumour purity and stromal and immune cell admixture from expression data.Nat. Commun.201341261210.1038/ncomms361224113773
     [Google Scholar]
  35. YuanZ. WangL. ChenC. Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors.Front. Oncol.20221296371910.3389/fonc.2022.96371936158677
     [Google Scholar]
  36. XuZ. PeiC. ChengH. SongK. YangJ. LiY. HeY. LiangW. LiuB. TanW. LiX. PanX. MengL. Comprehensive analysis of FOXM1 immune infiltrates, m6a, glycolysis and ceRNA network in human hepatocellular carcinoma.Front. Immunol.202314113852410.3389/fimmu.2023.113852437234166
     [Google Scholar]
  37. ChenB. DingX. WanA. QiX. LinX. WangH. MuW. WangG. ZhengJ. Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer.Sci. Rep.20231311624410.1038/s41598‑023‑42171‑537758722
     [Google Scholar]
  38. HuangZ. HuX. WeiY. LaiY. QiJ. PangJ. HuangK. LiH. CaiP. ADAMTSL2 is a potential prognostic biomarker and immunotherapeutic target for colorectal cancer: Bioinformatic analysis and experimental verification.PLoS One2024195e030390910.1371/journal.pone.030390938814950
     [Google Scholar]
  39. ShiB. ChuJ. HuangT. WangX. LiQ. GaoQ. XiaQ. LuoS. The scavenger receptor MARCO expressed by tumor-associated macrophages are highly associated with poor pancreatic cancer prognosis.Front. Oncol.20211177148810.3389/fonc.2021.77148834778091
     [Google Scholar]
  40. HandzlikG. SzymańskaE. PękalaE. KędzierskiL. StrzałkowskaD. DuławaJ. Low-sodium dietary approach in the management of resistant and refractory hypertension: Preliminary results.Pol. Arch. Intern. Med.2021131101609810.20452/pamw.16098
     [Google Scholar]
  41. ZhangY. ZhouY. WeiF. circABCB10 promotes malignant progression of gastric cancer cells by preventing the degradation of MYC.J. Oncol.2021202111410.1155/2021/462503334950208
     [Google Scholar]
  42. LuoJ. LiH. XiuJ. ZengJ. FengZ. ZhaoH. LiY. WeiW. Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT/mTOR signaling.Biomark. Res.20231113810.1186/s40364‑023‑00471‑y37038184
     [Google Scholar]
  43. IssamN.I. MarnissiF. LakhdarA. KarkouriM. ElBelhadjiM. BadouA. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.Front. Immunol.202314122514010.3389/fimmu.2023.122514037662962
     [Google Scholar]
  44. GelmiM.C. GezginG. van der VeldenP.A. LuytenG.P.M. LukS.J. HeemskerkM.H.M. JagerM.J. PRAME expression: A target for cancer immunotherapy and a prognostic factor in uveal melanoma.Invest. Ophthalmol. Vis. Sci.202364153610.1167/iovs.64.15.3638149971
     [Google Scholar]
  45. ZhuR. ChenY.T. WangB.W. YouY.Y. WangX.H. XieH.T. JiangF.G. ZhangM.C. TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma.BMC Cancer202323114610.1186/s12885‑023‑10527‑936774490
     [Google Scholar]
  46. LiangX. YinY. LiN. GOLM1 is related to the inflammatory/immune nature of uveal melanoma and acts as a promising indicator for prognosis and immunotherapy response.Front. Genet.202213105116810.3389/fgene.2022.105116836468024
     [Google Scholar]
  47. YeY. ChenZ. ShenY. QinY. WangH. Development and validation of a four-lipid metabolism gene signature for diagnosis of pancreatic cancer.FEBS Open Bio.202111113153317010.1002/2211‑5463.1307433386701
     [Google Scholar]
  48. ZhangW. YeY.J. RenX.W. HuangJ. ShenZ.L. Detection of preoperative chemoradiotherapy sensitivity molecular characteristics of rectal cancer by transcriptome second generation sequencing.Beijing Da Xue Xue Bao Yi Xue Ban201951354254710.19723/j.issn.1671‑167X.2019.03.025.
     [Google Scholar]
  49. MaD. LuytenG.P. LuiderT.M. NiederkornJ.Y. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model.Invest. Ophthalmol. Vis. Sci.19953624354417843912
     [Google Scholar]
  50. BaqaiU. PurwinT.J. BechtelN. ChuaV. HanA. HartsoughE.J. KuznetsoffJ.N. HarbourJ.W. AplinA.E. Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma.Mol. Cancer Res.20222081260127110.1158/1541‑7786.MCR‑21‑065735426938
     [Google Scholar]
  51. CrossN.A. MurrayA.K. RennieI.G. GaneshA. SisleyK. Instability of microsatellites is an infrequent event in uveal melanoma.Melanoma Res.200313543544010.1097/00008390‑200310000‑0000114512784
     [Google Scholar]
/content/journals/ppl/10.2174/0109298665341953240926041613
Loading
SGSM2 in Uveal Melanoma: Implications for Survival, Immune Infiltration, and Drug Sensitivity
PPL 31, 894 (2024); https://doi.org/10.2174/0109298665341953240926041613
/content/journals/ppl/10.2174/0109298665341953240926041613
/content/journals/ppl/10.2174/0109298665341953240926041613
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): calcium signaling pathway; immunotherapeutic; MSI; prognosis; SGSM2; Uveal melanoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test